Novavax to Present at the Jefferies Global Healthcare Conference

GAITHERSBURG, Md., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Stanley C. Erck, President and CEO, will present at the Jefferies Global Healthcare Conference to be held on Thursday, November 20, 2014 at 9:20 a.m. U.S. EST (2:20 p.m. GMT) at the Waldorf Hilton Hotel in London, UK.

A live webcast link for the presentation will be available via the company's website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000

You May Also Be Interested In

• Novavax (NVAX) 11K contracts of August 28 weekly 9 calls trade, share price up 8.8%
• Bitcoin Price Coils for a Breakout While Smart Wallets Race Into Pepeto Before Opens
• Nabanita De’s AI Privacy License Reshapes Digital Contracts for the AI Age